ResMed (ASX:RMD) Shares Going Ex-Dividend: What Income Investors Need to Know

Sonal Goyal

17 August 2026 05:37 PM AEST

ResMed (ASX:RMD) Shares Going Ex-Dividend: What Income Investors Need to Know

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

ResMed (ASX:RMD) is scheduled to go ex-dividend on 19 August 2026, with the ASX-listed distribution shown at 6.6 cents per CDI, payable on 24 September 2026.
ResMed reported FY26 Revenue of US$5.7 billion, up 10%, while GAAP Diluted Earnings per Share increased to US$10.43.
The company returned US$1.0 billion to shareholders during FY26 through dividends and share repurchases and announced plans to return more than US$1.85 billion during FY27.

ResMed (ASX:RMD) is among the healthcare stocks approaching an ex-dividend date this week, with its Australian-listed securities scheduled to trade ex-dividend on 19 August 2026. The supplied ASX Dividend data lists a final distribution of 6.6 cents per security, with no franking and a payment date of 24 September 2026. ResMed's latest results, released on 6 August, showed higher revenue, earnings and cash generation for fiscal 2026.

ResMed Reports Higher FY26 Revenue

ResMed reported fourth-quarter revenue of US$1.5 billion, an increase of 9% from the corresponding quarter. On a constant-currency basis, revenue increased 8%.

For the full fiscal year, revenue reached US$5.7 billion, representing a 10% increase, or 8% on a constant-currency basis. The company also reported higher profitability measures during the year, with GAAP gross Margin increasing 170 basis points to 61.1%.

Non-GAAP gross margin increased 240 basis points to 62.4%, while GAAP Operating Margin rose 70 basis points to 33.4%. Non-GAAP operating margin increased 180 basis points to 36.1%.

Earnings and Cash Flow Increase

ResMed's fourth-quarter GAAP diluted earnings per share increased 2% to US$2.64. Non-GAAP diluted earnings per share increased 16% to US$2.95.

For FY26, GAAP diluted earnings per share reached US$10.43, while non-GAAP diluted earnings per share increased 17% to US$11.17.

Cash generation also increased the resources available for Shareholder distributions and Business investment. ResMed reported FY26 Operating Cash Flow of US$1.8 billion and free cash flow of US$1.6 billion.

The company said its free cash flow supported Investment in innovation, continued development of its business and shareholder distributions during the year.

Dividend and Shareholder Returns

The dividend is an important part of ResMed's shareholder-return programme. The company's latest announcement included a quarterly dividend increase of 10%, taking the US dividend to US$0.66 per common share per quarter. ResMed had previously paid US$0.60 per common share per quarter. (investor.resmed.com)

For Australian investors, ResMed securities trade as CHESS Depositary Interests. ResMed has previously stated that ASX CDI holders receive the equivalent dividend in Australian currency based on the Exchange Rate on the relevant Record Date and reflecting the 10:1 CDI-to-NYSE-share ratio. (investor.resmed.com)

The supplied ASX dividend schedule lists the upcoming distribution at 6.6 cents per CDI, with the distribution classified as final and unfranked.

Shareholder Returns Exceed US$1 Billion

ResMed returned US$1.0 billion to shareholders through dividends and share repurchases during FY26, an increase of more than 70% from the previous year.

The company has also indicated that more than US$1.85 billion is expected to be returned to shareholders through dividends and share repurchases during FY27.

Alongside Capital returns, ResMed completed its Acquisition of Noctrix Health, a medical device company focused on wearable therapeutics for Restless Leg Syndrome. It also announced an agreement to sell its MatrixCare business, with completion expected during the first quarter of fiscal 2027.

Product and Business Developments

During the fourth quarter, ResMed launched AirSense 11 in Taiwan, while AirCurve 11 ST/ST-A was launched in the United States and AirTouch F30i Comfort was introduced in Brazil and Chile.

The company also announced a Partnership with ŌURA aimed at expanding access to sleep-health education and pathways to care.

These developments came as ResMed entered fiscal 2027 following a year in which revenue increased 10%, GAAP operating margin expanded and free cash flow reached US$1.6 billion.

Conclusion

ResMed enters its 19 August 2026 ex-dividend date following a fiscal year in which revenue increased 10% to US$5.7 billion and GAAP diluted earnings per share reached US$10.43. The ASX-listed distribution is shown at 6.6 cents per CDI and is scheduled for payment on 24 September, with no franking. ResMed also increased its quarterly US dividend by 10% to US$0.66 per common share and returned US$1.0 billion to shareholders during FY26. The latest figures therefore combine higher operating revenue, earnings and cash generation with an expanded shareholder-return programme.

FAQs

Q: When does ResMed (ASX:RMD) go ex-dividend?

A:ResMed is scheduled to go ex-dividend on 19 August 2026 according to the supplied ASX dividend calendar.

Q: How much is the ResMed ASX dividend?

A:The supplied ASX data lists the upcoming distribution at 6.6 cents per CDI.

Q: When will the ResMed dividend be paid?

A:The scheduled payment date is 24 September 2026.

Q: Is the ResMed dividend franked?

A:No. The supplied dividend data lists the distribution as 0% franked.

Q: Did ResMed's FY26 revenue increase?

A:Yes. FY26 revenue increased 10% to US$5.7 billion, while fourth-quarter revenue increased 9% to a record US$1.5 billion.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.